Curriculum Vitae

2006

Jennifer D Wallace

(Neuroendocrine Scientist)

Griffith University Learning Centre

GULC Annex, Logan Hospital

177 Armstrong & Loganlea Road

Meadowbrook

Queensland 4131

Australia.

Telephone: 07 3342 2797 (Home, MessageBank and Fax)

0412 667 533 (mobile), 07 3299 9596 (office)

e-mail: aghdaware@optusnet.com.au

•     Personal Details:

Name:                          Jennifer D Wallace

Address:                      Brisbane, Queensland, Australia.

Telephone:                  07 3342 2797 (H), 0412 667 533 (m), 07 3399 9596 (w)

Fax:                              07 3342 2797

E-mail:                         aghdaware@optusnet.com.au

D.O.B:                         10^th December 1963

Place of Birth:             England, United Kingdom

Residence Status:       Permanent Resident of Australia since 1990.

•     Notice required to commence new appointment: 7 days.

•     Back to Top

•     Referees who have been contacted and agreed to provide a reference for prospective employers of Jennifer Wallace:

•     Associate Professor Daryl Wall, MBBS (Hons), FRACS

Director of General Surgery                             

Senior Transplant Surgeon                               

Princess Alexandra Hospital

Ipswich Road, Woolloongabba,

Brisbane, Queensland 4102

Telephone:        07 3240 2767

Fax:                   07 3240 7011

Email:   daryl_wall@health.qld.gov.au

•     Prof Richard V Jackson, MBBS, BSc(Hons), FRACP

Director, Neuroendocrine Research Unit

Consultant, Endocrinology and Internal Medicine

Professor of Medicine, Logan Campus

School of Medicine

GRIFFITH UNIVERSITY

Logan Hospital

Meadowbrook  Qld 4131 Australia

Telephone 07 3299 8155

Fax 07 3299 8887

Email r.jackson@griffith.edu.au

OR:    rick_jackson@health.qld.gov.au

•     Leigh Atkinson AO, FRACS FACS FRCS (Edin.), FFPMANZCA FAFRM (RACP)

Neurosurgeon

Associate Professor, University of Queensland.

Postal Address:

Alexandra

201 Wickham Terrace

Brisbane, Qld 4000

Tel: 07 3839 3393

Mobile: 0412 022 282

Fax:       07 3832 2005

E-mail: leighatkinson@optusnet.com.au

•     Back to Top

•     History of Employment:

•     Back to Top

•     Academic Qualifications:

2006:   Currently writing up PhD on: The Detection of Growth Hormone (GH) Abuse by Elite Athletes: Studies  On The Effect of Exercise, GH Treatment and GH Withdrawal In  Human Male Athletes.

1998:   National Assessment in Respiratory Physiology (UK), 1988.

1987:   B.Sc. (Hons.), University of London, UK. Aug. 1987, (2.2).(Honours research project  on Physiological Correlates of Stress received  Ist Class award).

•     Courses Attended:

•     Authentic Happiness Coaching in the New Positive Psychology: Brisbane, 2004

               (12 weeks, 1 night per week, personal development and mentorship training).

•     Career Horizons for Women (management training):  University of Queensland, 2002.

•     Clinical Trials Statistics:  NHMRC Clinical Trials Centre, Sydney, 2001.

•     Clinical Trials Coordinators course:  Pharmacia, Sydney, 2001.

•     Resuscitation Coordinator Workshop: Princess Alexandra Hospital,  Brisbane, Australia, October 1995.

•     Microsoft Excel Macros:  University Of Queensland, May 1994.

•     Clinical Trials Statistics:  NHMRC Clinical Trials Centre, Sydney, 1994.

•     A Practical Course in Clinical Trials:  NHMRC Clinical Trials Centre, Sydney 1992.

•     Advanced Statistical analysis for Clinical Scientists:  University of Queensland, 1991.

•     Introduction to ORACLE:  University of Queensland, 1990.

•     Introduction to SPSSX:  University of Queensland, 1990.

•     Mountain Medicine:  St. Bartholemew Hospital, London 1989.

•     Clinical Respiratory Physiology:  Royal Postgraduate Medical school, Hammersmith Hospital, London, 1988.

•     Back to Top

•     Details of relevant professional, consulting or industry experience:

I have addressed these criteria below under the headings of:

•     Major Themes/Areas of Research In Which I Am Involved

•     Major Research Developments, Achievements and Outcomes:

•     Service Within The Hospital and University

•     External Service

•     Consultative And Related Outside Work

•     Major Themes/Areas of Research In Which I Am Involved:

Clinical Areas of Study

•         Adults with growth-hormone deficiency.

•         Adults with Acromegaly.

•         Normal adults including aged populations.

•         Veteran athletes.

•         Adults with Chronic Liver Disease.

•         Adults post liver transplantation.

•         Highly trained athletes.

I have worked in the Department of Medicine for 15 years researching growth hormone (GH) regulation, physiology and pathophysiology in normal subjects, ageing athletes, adults with growth hormone deficiency, adults with Acromegaly and adults with chronic liver disease; and most recently young male athletes as part of a large European based project funded by the International Olympic Committee and the European Union, (US$3,000,000), with the objective of developing a GH detection methodology for the 2000 Olympics.  I have recently completed the clinical aspect of a significant project as co-principal investigator and coordinator of the $355,584 NHMRC grant: Regulation and effect of the growth hormone, IGF-I, and IGF-Binding protein response to acute exercise, during which I extensively explored thermoregulation and intermediary metabolism, in growth hormone deficient adults;  I have recently been co-investigator on two projects with Acromegalic adults, one which compares medical vs surgical treatment in Acromegaly, and the other which investigates the efficacy of treatment with a novel somatostatin analogue.  I have also recently supervised a neuro-surgical registrar to develop a rat model of Acromegaly and to pursue our ideas of developing a novel treatment of pituitary tumours with a radio-labelled neuropeptide in collaboration with the Australian Nuclear Science and Technology Organization. On the basis of my publications in the area of GH physiology and GH doping, I was contacted by and am presently collaborating with the Australian Proteomic Analytical Facility in Sydney, in a grant application to the United States Anti Doping Agency for US$760,000. This application has been reviewed and a request for supporting preliminary data was made. I have performed some human experimentation to allow APAF to perform analytical work as preliminary data, and would like to create the opportunity to perform more human research work in Brisbane if funding becomes available.

•     Back to Top

•     Major Research Developments, Achievements and Outcomes:

In partnership with Ross Cuneo I have dedicated the last 15 years to performing carefully conducted experimenter driven clinical research, and some of the highlights and major achievements have been:

1. Performed some of the world’s first absorption profiles of recombinant human growth hormone in human adults in the 1980’s.

2. Set up the Metabolic Research Unit at Princess Alexandra Hospital in 1990 for purposes of conducting experimenter driven clinical research into physiology and pathophysiology of GH regulation.  Metabolic testing facilities included respiratory gas analysis, exercise testing, ECG assessment, body composition analysis (including anthropometry, swept frequency bioelectrical impedance and energy expenditure with  D₂0), 24 hour hormone profile determination, nutritional and metabolic status determination and estimation of resting metabolic rate.  More recently methods have been established for investigation of thermoregulation such as: infra-red photography, detection of sweat gland activation and density with hydrophobic polymer application, measurement of sweat gland activation and secretion rate with ventilated capsule capacitance hygrometry, skin blood flow detection and measurement of core temperature with rectal probes.

3. Single-handedly set up state of the art exercise physiology laboratory in St Thomas Hospital London with sponsorship by the IOC. Performed all validation work and wrote and implemented human physiology protocols.  Designed conducted and supervised studies from conception to pubication in highly cited, internationally recognised journals.

4. Contributed intellectually and practically to empirical research to demonstrate efficacy and safety of GH treatment in GH deficient adults world-wide.  Major contribution to the establishment in the world literature of an essential role for Growth Hormone in adult physiology, in the fields of body composition, exercise performance, cardiac function, lipid metabolism, and psychological function.  Contributed significantly to 10 year follow up of GH treatment in GH deficient adults which is considered as a landmark publication along with earlier treatment studies.

5. Major contributor to industry applications to Therapeutic Goods Administration resulting in authorization of prescription of GH for treatment of GH deficiency in adults and also recent application to government for PBS subsidization.

6. One of the first in the world to develop the concept that dysregulated GH/insulin-like growth factor-l axis may contribute to the catabolic process of cirrhosis, and to treat patients with supraphysiologic doses of GH with the aim of overcoming that GH resistance.  Probably first in the world to perform a detailed treatment trial, but not first published due to manpower limitations. (This was my 2nd PhD project).

7. First to characterize the GH/IGF axis and define the endogenous secretory pattern of GH in patients with liver cirrhosis both before and after liver transplantation.

8. First in the world literature to discover the profound effect of GH on antinatriuresis and contribution to clinically significant ascites and oedema in patients with cirrhosis: leading to potential novel therapeutic strategies in the treatment of resistant ascites.

9. First in the world to study the effect of strenuous exercise on the diurnal, endogenous GH secretory profiles in adult humans.

10. Significant efforts to explore the concept that some of the detrimental effects of ageing are mediated by reductions in endogenous GH production, as a result of diminution of physical activity. (This was my masters’ project which got turned into a PhD project!).

11. Significant contribution to the efforts to develop a program to detect GH and IGF-1 abuse in Olympic athletes: studies funded by the European Union and the International Olympic Committee.  World-first systematic study of the effects of exercise, GH administration and exercise, and GH withdrawal on potential markers of GH abuse in athletes.  Studies led to new understandings of the effect of the GH/IGF axis on normal exercise physiology. (This was my 3^rd PhD project!)

12. Significant contribution to establishing a rat model of Acromegaly, and investigating the development of radio-labeled neuro-peptides in the treatment of Acromegaly. (This was my second post-doc project!).

13. Significant contribution to working protocols for the investigation of novel therapeutic approaches for industry developed pharmaceutical treatment of Acromegaly.

14. Design and execution of Innovative and highly technical systematic study of thermoregulation and regulation of GH/IGF system in growth hormone deficiency before and after growth hormone treatment. (This was my first post-doc project!)

15. Developing a world-wide reputation for innovative and carefully conducted experimenter driven research.

16. Significant contribution to establishing an Australia-wide registry for Acromegaly.

17. Developing an international reputation for expertise in GH neuroendocrine physiology and sport.

18. Establishing collaboration on a global scale in a diverse range of clinically relevant fields.

19. To have succeeded in obtaining funding from a wide range of granting bodies both internal and external, national and international including the coveted NH$MRC award!

•     Back to Top

•     Service Within The Hospital And University:

The wide range of roles I have performed in my career as a researcher over the years, both in active research and supervision, have given me a great breadth of practical experience in management of both students and co-workers.

I have contributed widely to Problem Based Learning in the Graduate Medical Course as outlined in the response to selection criteria above.

I have provided mentorship both officially and to the wider student and staff community in both the hospital and university for many years and the practical effectiveness of my skills will be evident from the references provided.

•     External Service:

•     Back to Top

•     Consultative and Related Outside Work:

•     Back to Top

•      Publications:  Jennifer Wallace 2006

•     Book Chapters:

1.  Wallace JD and Cuneo RC.  Growth Hormone and Sport.  The Endocrine System In Sports and Exercise, Olympic Encyclopaedia of Sports Medicine Volume XI, Edited by Kraemer W and Rogol A, Blackwell Publishing, 2005.

2.  Cuneo RC and Wallace JD. Skeletal and Cardiac Muscle in Adults with Growth Hormone Deficiency. In: Frontiers of  Hormone Research, vol. 33, Growth Hormone Deficiency in Adults, pp 121-145, Edited by J.O.L. Jorgensen and J.S. Christiansen, series editor A.B. Grossman, Karger 2005.

3.  Sönksen PH, Wallace JD, Cuneo RC.  Growth hormone abuse  in elite athletes.  in “Drug Abuse Handbook”, S.B. Karch, M.D. (ED), CRC Press, Boca Raton, Florida, 1997. pp 690-710

•    Papers:

4. Olson SL, Wallace JD, Atkinson L and Cuneo RC.  Benign Intracranial Hypertention Associated With Acormegaly.  The Endocrinologist 2005; 15 (3), 1-4.

5. Wallace JD, Abbott-Johnson WJ, Crawford DHG, Barnard R, Potter J, Cuneo RC.  GH treatment in adults with chronic liver disease: a randomised, double-blind, placebo-controlled, cross over study.  Journal of Clinical Endocrinology and Metabolism 2002, 87(6): 2751-2759.

6. Wallace JD, Cuneo RC, Bidlingmaier M, Lundberg P-A, Carlsson L, Boguszewski CL, Hay J, Healy M-L, Napoli R, Dall R, Rosen T, Strasburger CJ.  The response of molecular isoforms of growth hormone (GH) to acute exercise in trained adult males.  J Clin Endocrinol Metabol 2001; 86(1):200-206.

7. Wallace JD, Cuneo RC, Bidlingmaier M, Lundberg P-A, Carlsson L, Boguszewski CL, Hay J, Boroujerdi M, Cittadini A, Dall R, Rosen T, Strasburger CJ  Changes in non-22-kilodalton (kDa) isoforms of growth hormone (GH) after administration of 22kDa recombinant human GH in trained adult males.  J Clin Endocrinol Metabol 2001; 86(4):1731-37.

8. Cuneo RC and Wallace JD.  Adult growth hormone deficiency: what does the newest hormone replacement therapy do?  Current Therapeutics 2001; 42(12/1):43-47.

9. Wallace JD, Cuneo RC.  Growth hormone and sport.  Int. Growth Monitor, 2000, 10(2):2-6.

10. Wallace JD, Cuneo RC.  Growth hormone abuse in athletes: a review.  The Endocrinologist, 2000, 10:175-184.

11. Wallace JD,  Cuneo RC, Lundberg PA, Rosen T, Jorgensen JOL, Longobardi S, Keay N, Sacca L, Christiansen JS, Bengtsson BA, Sonksen P.  Responses of markers of bone and collagen turnover to exercise, growth hormone (GH administration and GH withdrawal in trained adult males.)  J Clin Endocrinol Metabol 2000, 85(1):124-133.

12. Dall R, Longobardi S, Ehrnborg C et al on behalf of the GH2000 Study Group (Includes Wallace JD and Cuneo RC).  The effect of four weeks of supra-physiological growth hormone administration on the IGF-axis in women and men.  J Clin Endocrinol Metabol 2000, 85(11):4193-4200.

13. Longobardi S, Keay N, Ehrnborg C et al on behalf of GH2000 Study Group (Includes Wallace JD and Cuneo RC).  Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study.  J Clin Endocrinol Metabol 2000, 85(4):1505-12.

14. Wallace JD,  Cuneo RC, Baxter R, Orskov H, Keay N, Pentecost C, Dall R, Rosen T, Jorgensen JO, Cittadini A, Longobardi S, Sacca L, Christiansen JS, Bengtsson BA, Sonksen PH.  Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration and GH withdrawal in trained adult males: a potential test for GH abuse in sport.  J Clin Endocrinol Metabol 1999, 84(10):3591-3601.

15. Meeking DR, Wallace JD, Cuneo RC, Forsling RC, Russell-Jones DL.  Exercised-induced GH secretion in enhanced by the oral ingestion of melatonin in healthy adult male subjects.  European Journal of Endocrinology 1999, 141(1):22-6.

16. Gibney J, Wallace JD Spinks T, Schnorr L, Ranicar A Cuneo RC, Lockhart S, Burnand KG, Salomon F, Sonksen PH, rusell-Jones D.  The effects of 10 years of recombinant human growth hormone in adult growth hormone deficient patients.  J Clin Endocrinol Metabol 1999, 84(8):2596-2602.

17. Cuneo RC, Judd S, Wallace JD, Perry-Keene D, Burger H, Lim-Tio S, Strauss B, Stockigt J, Topliss D, Alford F, Hew L, Bode H, Conway A, Handelsman, D, Dunn S, Boyages S, Cheung W, Hurley D.  The Australian Multi-centre Trial of Growth Hormone Treatment in Growth Hormone Deficient Adults.  J Clin Endocrinol Metabol 1998; 83:1:107-116.

18. Cuneo RC, Hickman P, Wallace JD, The BT, Ward G, Veldhuis JD, & Waters MJ.  Altered endogenous growth hormone secretory kinetics and diurnal GH-binding protein profiles in adults with chronic liver disease.  Clin Endocrinol. 1995;  43: 265-275.

19. Cuneo RC & Wallace JD.  Growth hormone, insulin-like growth factors and sport. Endocrinol Metabolism. 1994; 1: 3-13.

20. Crawford DHG, Halliday JW, Cooksley WGE, Murphy TL, Golding SM, Wallace JD, Cuneo RC, Lynch SV, Strong RJ, & Powell LW.  The distribution of body water in patients with cirrhosis: The effect of liver transplantation.  Hepatology 1993; 17: 1016-1021

•     Abstracts:

21. Pratt EJ, Wallace JD, Cuneo RC. Reduced Sweating Before and After Vigorous Exercise In Growth Hormone Deficient Adults. Proceedings of the 2nd International GH-IGF Symposium, April 2004, Cairns Australia.

22.  Pratt EJ, Wallace JD, Cuneo RC. Prevalence of growth hormone deficiency in a tertiary referal centre. Proceedings of the 44th Annual Scientific Meeting, Endocrine Society of Australia, Gold Coast, September 2001, #423.

23. *Wallace JD, Cuneo RC, Bidlingmaier M, Rosen T, Lundberg PA, Carlsson L, Hay J, Sonksen PH, Sacca L, Dall, Strasburger. Detection of exogenous 22kDa growth hormone (GH) by suppression of the proportion of non-22-kDa isoforms in exercising, trained adult males. Proceedings of 11th International Congress of Endocrinology, Sydney October 2000, p.194.

24. *Wallace JD, Cuneo RC. Misuse of growth hormone. Novo Nordisk Satellite Symposium to ICE 2000.

25. *Wallace JD, Cuneo RC, Bidlingmaier M, Sonksen PH, Sacca L, Christiansen JS, Lundberg PA, Strasburger CJ. The response of molecular isoforms of growth hormone (GH) to acute exercise in trained adult males. Growth Hormone & IGF Research, 2000, 10(3):134.

26. *Wallace JD, Cuneo RC. Developments on the GH2000 project in the lead up to the 2000 Olympics. Drugs in Sport, 1999 vol. 10: 11.

27. Ehrnborg C, Lange K, Baxter R, et al on behalf of the GH2000 Study Group (includes J.D.Wallace). GH/IGF-1 and related parameters in elite athletes- a longitudinal study. Proceedings US Endocrine Society’s 81st Annual Meeting, 1999. P.574.

28. Healy ML, Dall R, Ehnrborg C et al on behalf of the GH2000 Study Group (includes J.D.Wallace). GH/IGF-1 and related parameters in elite athletes – a post competition, cross-sectional study. Proceedings US Endocrine Society’s 81st Annual Meeting, 1999. P.575.

29. Longobardi S, Keay N, Ehrnborg  C et al on behalf of the GH2000 Study Group (includes J.D.Wallace). Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential usefulness in the detection of GH sport abuse. A double blind, placebo-controlled study. Proceedings US Endocrine Society’s 81st Annual Meeting, 1999. P.394.

30.  Dall R, Longobardi S, Ehrnborg C, et al on behalf of the GH2000 Study Group (includes J.D.Wallace). IGF related markers of supraphysiological exogenous GH exposure in 102 adult healthy young adults. Proceedings US Endocrine Society’s 81st Annual Meeting, 1999. P.81.

31. Boroujerdi MA, Dall R, Keay N, et al on behalf of the GH2000 Study Group (includes J.D.Wallace). Stimulation of growth hormone dependant markers during and following growth hormone treatment. Proceedings US Endocrine Society’s 81st Annual Meeting, 1999. P.397.

32. *Wallace JD, Cuneo RC. Development of a detection system for the use of growth hormone in sport. Proceedings Endocrine Society of Australia’s 42nd Annual Meeting, 1999. P51.

33. *Wallace JD, Wu Z, Bidlingmaier M, on behalf of the GH2000 Study Group. Molecular isoforms of growth hormone (GH) in the detection of exogenous GH administration in athletes. Proceedings Endocrine Society of Australia’s 42nd Annual Meeting, 1999. P 66.

34. Cuneo RC, Wallace JD. The use of growth hormone as a drug of abuse in sport. Proceedings Endocrine Society of Australia’s 42nd Annual Meeting, 1999. P50.

35. Gibney J, Wallace JD, Spinks T, Burnand K, Cuneo R, Salomon F, Sönksen P  and Russell-Jones D. The effects of 10 years of recombinant Human Growth Hormone in adult growth hormone deficient patients. Journal of Endocrinology March 1998, vol 156, supplement, #P191.

36. Gibney J, Wallace JD, Spinks T, Burnand K, Cuneo R, Salomon F, Sönksen P  and Russell-Jones D. The effects of 10 years of recombinant Human Growth Hormone in adult growth hormone deficient patients. Proceedings of the European Congress of Endocrinology, Seville, Spain, May 1998.

37. Gibney J, Wallace JD, Spinks T, Burnand K, Cuneo R, Salomon F, Sonksen P  and Russell-Jones D. 10 years of replacement with recombinant human growth hormone in adult growth hormone deficient patients. The 80th Annual Meeting of the Endocrine Society, New Orleans, June 1998.

38. P.Burman on behalf of the The Australian Adult Growth Hormone Study Group (includes J.D.Wallace). The effects of body composition and serum IGF-1 during treatment with genotropin in adult patients with multiple pituitary hormone deficiencies as compared with patients with isolated GHD. US Endocrine Society Meeting, New Orleans, June 1998.

39. P.Burman, Anni Sietnieks, Patrik Ohagen on behalf of the Study Group for Adult GHD (includes J.D.Wallace). Predicting the response of growth hormone treatment experience in 709 adults with GH deficiency. US Endocrine Society Meeting, New Orleans, June 1998.

40. Ross C Cuneo and Jennifer D Wallace. Doping in sport, an overview. The Clinical Biochemist Reviews 1998;19:(iii):70, Proceedings of the Australasian Association of Clinical Biochemists, 36th Annual Scientific Conference, Brisbane, August 1998.

41. *Jennifer Wallace, Ross C Cuneo, Robert Baxter, Thord Rosén,  B-Å Bengtsson, R. Dall, Jens-Otto Jorgensen, Hans Orskof, Antonio Cittadini, Salvatore Longobardi, Luigi Sacca, Claire Pentecost, Marie-Louise Healey, Peter Sönksen. Endocrine markers of growth hormone  abuse in sport. Proceedings of the 41st Annual Scientific Meeting, Endocrine Society of Australia, Perth, August 1998, volume 41, p.55, abstract #7.

42. Ross  C. Cuneo, Jennifer D Wallace, Thord Rosén, Per-Arne Lundberg, Beng-Åke Bengtsson, R Dall, Jens O.L. Jorgensen, Jens S Christiansen, Antonio Cittadini, Salvatore Longobardi, Luigi Sacca, Claire Pentecost, Nicola Keay, Peter Sönksen. Use of bone markers to detect growth hormone abuse in sport. Proceedings of the 41st Annual Scientific Meeting, Endocrine Society of Australia, Perth, August 1998, volume 41, p.55, abstract #8.

43. Catherine S Choong, Jennifer D Wallace, David Cowley, Ross C Cuneo. Prostate specific antigen levels following GH treatment in GH deficient adults. Proceedings of the 41st Annual Scientific Meeting, Endocrine Society of Australia, Perth, August 1998, volume 41, p.74, abstract #45.

44. *JD Wallace, RC Cuneo, R Baxter, T Rosén,  B-Å Bengtsson, R Dall, JO Jorgensen, C Pentecost, ML Healey, A Cittadini, S Longobardi. Detection of growth hormone abuse in athletes. Growth Hormone & IGF Research Vol 8:4:329, August 1998,abstract #O66  of the Growth Hormone Research Society Conference, San Francisco, 3-7 September 1998.

45. JD Wallace, RC Cuneo,  T Rosén,  B-Å Bengtsson, P-A Lundberg, R  Dall,JS Christiansen, C Pentecost, N Keay, A Cittadini,  S Longobardi. Bone Markers and Growth Hormone (GH) Abuse in Athletes. Growth Hormone & IGF Research Vol 8:4:348, August 1998,abstract #P71  of the Growth Hormone Research Society Conference, San Francisco, 3-7 September 1998.

46. ML Healy, J Gibney, J Wallace, P Sönksen & D Russell-Jones. A comparison of three methods of assessing body composition in growth hormone-deficient adults. Growth Hormone & IGF Research Vol 8:4:345, August 1998,abstract #P63  of the Growth Hormone Research Society Conference, San Francisco, 3-7 September 1998.

47. ML Healy, J Gibney, J Wallace, R Cuneo, P Sönksen, D Russell-Jones. The effects of 10 years of recombinant human growth hormone  ( Psychological Well-Being). Growth Hormone & IGF Research Vol 8:4:349, August 1998, abstract #P75 of the Growth Hormone Research Society Conference, San Francisco, 3-7 September 1998.

48. J Gibney, J Wallace, A Wierzibicki, R Cuneo, F Salomon, P Sönksen & D Russell-Jones. The effects of 10 years of recombinant human growth hormone (Lipid Status). Growth Hormone & IGF Research Vol 8:4:349, August 1998, abstract #P76  of the Growth Hormone Research Society Conference, San Francisco, 3-7 September 1998.

49. *Jennifer D Wallace and Ross C Cuneo. Endocrine markers of growth hormone  abuse in sport: Invited lecture (NB same title but different content to ESA Abstract). Proceedings of the Sports Medicine Australia Conference, Perth, October 1998.

50. Cuneo RC, Alford F, Burger H, Handelsman D, and the Adult GH Deficiency Study Group (includes J.D.Wallace). Responsiveness to GH treatment in adults with GH deficiency: comparison of those patients with normal vs sub-normal pre-treatment serum IGF-I. Endocrine Society of Australia’s annual scientific meeting, Canberra 1997, abstract #106.

51. Burman P, Sietnieks A, Öhagen P, and The Study Group for Adult GHD (includes J.D.Wallace). Patients with isolated GH deficiency have a similar responsiveness to GH treatment as patients with multiple pituitary hormone deficiencies. European Neuroendocrine Association meeting, Sept 1997, Marseilles, France.  Published in supplement to “Annales d’Endocrinologie”.

52. Meeking DR, Wallace JD, Cuneo RC, Mullan G, Sharma S, Sawyer A, Forsling M, Russell-Jones D. Exercise-induced growth hormone secretion is enhanced by the oral ingestion of melatonin in healthy adult male subjects. Clin Endocrinol 1997;. A25.

53. *Wallace JD, Cuneo RC, Alford F, Handelsman D, Burger H and the Adult GH Deficiency Study Group. Prediction of response to GH treatment in adults with GH deficiency: comparison of those patients with  normal vs sub-normal pre-treatment serum IGF-I. Proceedings of the 24th International Symposium of Growth Hormone and Growth Factors in Endocrinology and Metabolism, Antwerp, Belgium 1997.

54. P.Burman, Anni Sietnieks, Patrik Öhagen and The Study Group for Adult GHD (includes J.D.Wallace). The responsiveness to growth hormone treatment is similar in patients with isolated growth hormone deficiency and those with multiple pituitary hormone deficiencies. Proceedings of the 24th International Symposium of Growth Hormone and Growth Factors in Endocrinology and Metabolism Antwerp, Belgium, 1997.

55. P.Burman, Anni Sietnieks, Patrik Öhagen and The Study Group for Adult GHD (includes J.D.Wallace). The effects of body composition and serum IGF-I during treatment with genotropin in adult patients with multiple pituitary hormone deficiencies as compared with patients with isolated GHD. Poster abstract presented at (i) The 8th Meeting of the European Neuroendocrine Association, September 1997, Marseilles, France, and (ii) the 24th International Symposium on Growth Hormone and Growth Factors in Endocrinology and Metabolism Antwerp, Belgium, 1997.

56. *Wallace JD, Cuneo RC, Abbott W. Growth hormone treatment in adults with liver cirrhosis: effects on body composition and metabolism. 10th International Congress of Endocrinology, San Francisco, June 1996:  #OR37-6.

57. Australian Multicentre Adult GHD study Group: Burger H, Alford F, Bode H, Boyages S, Cheung W, Conway A, Cuneo R, Handelsman D, Hew L, Hurley D, Judd S, Lim-Tio S, Perry-Keene D, Stogkigt J, Strauss B, Topliss D, Wallace J. Impact of growth hormone therapy on cardiovascular risk factors and body composition in adult growth hormone deficiency. Proc Endo Soc Australia 1995; 38: 129.

58. *Wallace JD, Cuneo RC, Yandle T, Espiner EA. Growth hormone (GH) treatment in adults with GH deficiency: effects on distribution of body water and volume regulatory hormones. Proc Endo Soc Australia 1995; 38: 130.

59. *Wallace JD, Cuneo RC. Growth hormone treatment in adults with liver cirrhosis. Proc Aust Parenteral and Enteral Nutrition Society. 1995; 40.

60. Cuneo RC, Hickman P, Wallace JD, Teh BT, Ward G, Veldhuis JD, Waters MJ. Diurnal growth hormone (GH) and GH‑binding protein profiles in adults with chronic liver disease. Endo Soc Australia Proc 1993; 36: 21.

    Back to Top

•     Non Refereed Publications and Original Contributions:

A Meta-Analysis and Review of Responses to GH Treatment in GH Deficient Adults

Ross C Cuneo and Jennifer D Wallace

Commissioned by Novo Nordisk 2001

•     Special Report to the International Olympic Committee and the European Union:

GH-2000 A Methodology for the Detection of Doping with Growth Hormone and Related Substances,

A Biomed 2 Project, Contract Number: BMH4 CT950678.

Prof. R.Baxter, Prof. B. A. Bengtsson, Dr E. Bassett, Prof P Brown, Prof J.S. Christiansen, Dr R. Cuneo, Dr L  Fryklund, Dr A-M Kappelgaard, Dr M. Kenward, Prince Alexander De Morode, Dr L  Rivier, Prof. L. Sacca, Dr M Saugy, Prof. P. Sonksen, Dr C. Strassburger, J.D. Wallace.

•     Community Service:

•     Back to Top

This Page Refreshed: Saturday, 12. April 2008

This Website Created:  Tuesday, 01, August, 2006